Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 73

Results For "quarter"

884 News Found

AsterDM Healthcare Q3FY22 PAT at Rs 148.34 cr.
News | February 08, 2022

AsterDM Healthcare Q3FY22 PAT at Rs 148.34 cr.

Aster DM Healthcare has reported consolidated financial results for the period ended December 31, 2021


Biosynthetic Technologies raises $7.5 million
News | February 08, 2022

Biosynthetic Technologies raises $7.5 million

Biosynthetic Technologies produces estolides, a new class of biobased synthetic oils used in a number of applications, including motor oil, industrial lubricants, pharmaceuticals, and personal care.


Caplin Point’s Q3 in line; outlook positive amid expansion plans: ICICI Direct
News | February 07, 2022

Caplin Point’s Q3 in line; outlook positive amid expansion plans: ICICI Direct

Key takeaways of recent quarter & conference call highlights


Lay Sciences launch ImmynlgY, an oral antibody to neutralize Covid-19
Biotech | February 07, 2022

Lay Sciences launch ImmynlgY, an oral antibody to neutralize Covid-19

ImmunIgY, has been developed by ReaGene Biosciences, Kyntox Bio and ProdigY, and is an antibody-containing beverage that can potentially prevent viral entry, regardless of vaccination or infection status


Sun Pharma demonstrates strong performance on all fronts: ICICI Direct
News | February 04, 2022

Sun Pharma demonstrates strong performance on all fronts: ICICI Direct

Sun Pharma’s Q3FY22 operational performance was in line with I-direct estimates with sustained momentum and good growth across businesses


Cadila Healthcare reports Q3FY22 net profit at Rs. 500.4 Cr
News | February 03, 2022

Cadila Healthcare reports Q3FY22 net profit at Rs. 500.4 Cr

The company has reported total income of Rs. 3715.8 crores during the quarter ended December 31, 2021


Cipla has strong traction in India and the US: ICICI Direct
News | January 31, 2022

Cipla has strong traction in India and the US: ICICI Direct

ICICI Direct’s analysis of Cipla’s Q3FY22 results


ARVs bottom out while CRAMS growth continues for Laurus Labs: ICICI Direct
News | January 29, 2022

ARVs bottom out while CRAMS growth continues for Laurus Labs: ICICI Direct

The management guided for ARV API & formulation demand to be normalised from Q4FY22 and reiterated the aspiration of US $ 1 billion in sales by FY23: ICICI Direct


Cipla’s Q3FY22 PAT at Rs 729 cr.
News | January 26, 2022

Cipla’s Q3FY22 PAT at Rs 729 cr.

Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.


Astec LifeSciences Q3FY22 PAT at Rs 24.74 cr.
News | January 26, 2022

Astec LifeSciences Q3FY22 PAT at Rs 24.74 cr.

Astec LifeSciences has reported its financial performance for the quarter ended December 31, 2021